4D Molecular Therapeutics Investor Day 2026 - 4D MOLECULAR THERAPEUTICS INC

Explicit Guidance:

• Financial/Operational Guidance: No specific quantitative guidance for revenue, earnings, margins, or capital expenditure was provided; management explicitly stated it is "too early to discuss pricing."
• Timeline for Results: Forefront 1 (Phase 3, North America) readout expected in Q1/Q2 2027; Forefront 2 (Phase 3, Global) readout expected in the second half of 2027.
• Cash Runway: Financial position supports operations into the second half of 2028.

Business-Segment Outlook:

• Product Launch & Adoption: 4D150 is projected to become the "backbone therapy" for all wet AMD patients, aiming for a paradigm shift from episodic bolus treatment to a single-injection continuous therapy.
• Treatment Trajectory: Management anticipates immediate commercialization focusing on the "high-need" population (approx. 25% of eyes requiring 8+ annual injections), expanding to moderate (45% of eyes) and low-burden patients over time.
• Patient Volume: Estimated 600,000 wet AMD patients treated in the US today, growing to 900,000 eyes by 2030; combined wet AMD/DME market projected to reach 1.7 million treated eyes in the US by 2030.
• Bilateral Treatment: Regulatory requirement for fellow-eye program is underway; expectation is to launch with the ability to treat bilateral disease, likely timing the second eye injection 3–6 months after the first (post-corticosteroid taper).

Market and Competitive Outlook:

• Market Size: Global wet AMD/DME market valued at ~$16 billion (60% in US); average market growth 5% over the last decade driven by aging demographics and new products.
• Competitive Gap: Current innovative agents (e.g., bevacizumab, faricimab) have only extended treatment intervals by ~12 days (from 55 to 67 days) over 5 years; no competitor offers continuous disease control or the potential for injection-free status.
• Adoption Velocity: Initial uptake expected in Year 1 (testing reimbursement via anonymous J-code); broad adoption and market maturity (beyond high-need patients) anticipated 2–4 years post-approval, driven by permanent J-code acquisition (estimated 9 months post-approval) and payer confidence.
• Patient Demand: 90% of patients surveyed expressed willingness to ask physicians about 4D150; strong patient-driven demand expected to accelerate adoption similar to prior gene therapy experiences.

Macro / Industry Outlook:

• Payer Landscape: Primary payers are Medicare (90% of market: 37% Fee-for-Service, 51% Medicare Advantage); reimbursement modeled on existing "Buy and Bill" model (Medicare Part B).
• Stakeholder Alignment: 87% of payers acknowledge the need for improved wet AMD therapy; 71% view gene therapy as the mechanism with the most potential to address unmet needs.
• Regulatory Status: Alignment secured via FDA RMAT designation, EMA Prime, and PMDA interactions in Japan; study designs optimized for broad global approval.
• Economic Implications for Clinics: Transition to 4D150 is expected to capture "lost value" from patient attrition (currently ~47% value erosion due to drop-off) by securing upfront reimbursement for lifelong treatment, enhancing clinic economics by reducing visit overhead.

Strategic Initiatives:

• Commercialization Model: Utilization of the existing "Buy and Bill" reimbursement infrastructure; no surgical implant or special equipment required, allowing seamless integration into standard intravitreal injection workflows.
• Manufacturing & Safety Profile: Proprietary R100 capsid and low-dose strategy (3E10) designed to minimize toxicity; prophylactic 20-week corticosteroid taper planned to manage episodic inflammation.
• KOL Engagement: Leveraging deep relationships with top 1,250 retina specialists (representing 90% of volume) and 10 major organizations (25% of volume) for early adoption.

Risks and Headwinds to Outlook:

• Clinical & Safety Risks: Potential for inflammation (managed via topical steroids), cataract progression (viewed as manageable/inevitable), and intraocular pressure spikes; risk of patient non-adherence to steroid taper.
• Reimbursement Risks: Dependence on obtaining a permanent J-code for streamlined billing; uncertainty in payer coverage expansion for higher-priced therapies.
• Operational Risks: Real-world adherence challenges (patients dropping off therapy due to logistics/health issues) could impact market perception if not mitigated by the "continuous" benefit.
• Trial Design Risks: Need to strictly manage supplemental injection criteria to protect visual acuity primary endpoints; exclusion of outliers is necessary to ensure non-inferiority to aflibercept.

Management Tone on the Future:

• Confidence Level: High confidence and optimism; CEO David Kern describes the company as "on the cusp" of realizing its 10-year vision.
• Strategic Clarity: Management emphasizes that 4D150 is "by design" to address the chronic nature of wet AMD, contrasting sharply with the "mismatch" of current episodic therapies.
• Commercial Assurance: Strong belief in the alignment of all stakeholders (patients, physicians, payers) driving broad commercial adoption; KOLs expressed enthusiasm and intent to prescribe immediately upon approval, even for treatment-naive patients.

Miscellaneous:

• Investor Relations: Q&A conducted via QR code; forward-looking statements disclaimer issued regarding SEC filings.
• Clinical Data Highlights: Phase 2b showed 46% of eyes injection-free for 2 years (overall) and 67% with ≤2 injections; 78% treatment burden reduction vs. aflibercept q8w.
• Key Opinion Leader Sentiment: KOLs noted that while current long-acting agents extend intervals slightly, the "anxiety" of bolus treatment remains; 4D150 is viewed as the solution to eliminate this anxiety and the risk of vision loss during treatment gaps.